DaVita (DVA)
NYSEHealth CareMedical - Care FacilitiesSnapshot 2026-10-30
$187.50-3.01%
Close 2026-10-30 · 1-day change
NYSEHealth CareMedical - Care FacilitiesSnapshot 2026-10-30
Research Workspace
Put DVA beside peers and holdings, graph the same metric, and keep your notes with the evidence.
Daily closes. Earnings/event dots are placed inline.
Industries move in repeating boom-and-bust cycles. This shows where this stock’s industry sits in that cycle, stage by stage (recovery → expansion → supercycle → steady → deceleration → contraction), from its fundamentals (orders, revenue, capital spending), not the stock’s price.
A booming industry is a tailwind for the names in it; a contracting one is a headwind. Companies in the same industry tend to rise and fall together with the cycle, the way a tide lifts and lowers every boat in the harbor at once, so a large part of a stock’s swing can come from where its industry sits rather than from the company itself. It’s context for reading the company’s results, not a buy/sell call. Full explanation →
Health Care is in steady. Describes the industry's cycle state, not a call on this stock.
The stage band shows the industry’s cycle over the chart’s timeline (each color a stage); a ▼ marks a quarter its growth inflected down — amber is an unconfirmed watch, red is confirmed the next quarter. Use “Overlay cycle on chart” to tint the price chart by stage. The industry’s fundamentals, not a signal on this stock.
Management is running behind on a stated commitment.
View ThesisRevenue is growing steadily — about 6% over the past year.
View GrowthRanks among the strongest in its industry on quality — around the top 9%.
View QualityManagement screens strong on margins, the balance sheet.
View ManagementExpectations look reasonable — what the market is pricing in sits in line with or below what analysts forecast.
View ValuationThis stock is volatile — it swings about 1% on a typical day and fell roughly 28% in its worst 12-month stretch.
View RiskDaVita’s case rests on strong recent financial performance and maintaining adjusted operating income guidance. Recent earnings beat, though the desk provides no revenue-growth figures. DVA trades at 15× P/E versus the 22× peer median. The price reflects less growth than our forecast. Management running behind on a stated commitment threatens the thesis. Our model puts the next-quarter miss probability near 33%. Peer multiples imply a price about 52% above where it trades. The thesis is on watch, and this read is provisional.
Trailing returns as of 2026-10-30. DVA is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 8 analysts currently covering DVA (as of Oct 2026).
Based on 6 Wall Street analysts offering 12-month price targets for DVA in the last 4 months.
Continue this research
Compare DVA with peers and holdings, graph the same reported metric, keep your questions beside the evidence, and return when the facts change.
Compare now without an account. Saving and monitoring require an account.
| Compare | Company | Living FV | P/E | Revenue % | Quality |
|---|---|---|---|---|---|
| DVA Selected company | Graph | Compare | Trend | Review | |
| Peer Add a competitor | Graph | Compare | Trend | Review | |
| Holding Compare a holding | Graph | Compare | Trend | Review |
Selected metric trend
Quarterly · checked companies · value or % of revenue
A consensus fair price across 9 valuation methods, at three horizons. As of 2026-10-30. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Health Care Services — fair value, gap to price, and forward P/E.
Compare the value case
Put DVA next to peers and holdings, compare Living FV and multiples, then graph the driver behind the difference.
Advances: Maintain adjusted operating income guidance
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-10-30. EPS is implied from price ÷ P/E. Not investment advice.
Current $187.50
The last 12 months of price, then the range of analyst 12-month targets from today’s $187.50.
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.
Around the middle on quality vs scored peers
A second lens on the 12-month fair value: for companies that score high on measured quality (profitability, balance-sheet safety, earnings stability), this read trusts more of today's profit margins instead of averaging them toward their multi-year history the way the headline number does. Shown alongside the fair value above, not in place of it. A diagnostic, not a price target or a buy/sell signal.
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
Company outlook confirms substantial adjusted operating income guidance and raises the IKC target.
Threatens: Maintain and achieve operating income guidance
Disappointing earnings outlook threatens operating-income guidance and weighs on the intact thesis.
Advances: Maintain and achieve operating income guidance
AI strategy aligns with growth and operating income guidance.
Advances: Maintain and achieve operating income guidance
AI strategy aligns with operating income growth guidance.
Advances: Maintain and achieve operating income guidance
Upgrade to Buy indicates positive outlook for operating income.
Advances: Maintain and achieve operating income guidance
Strong volume growth supports operating income guidance.
Threatens: Maintain and achieve operating income guidance
Earnings beat but stock drop raises concerns about guidance.
Advances: Expand integrated kidney care (IKC) patient base
Expansion of IKC patient base with AI tools is significant.